Mark Approval

ATS Medical Announces CE Mark Regulatory Approval for ATS CryoMaze(TM)

PR News Wire (Free subscription) | 08/14/2008

MINNEAPOLIS, Aug. 14 /PRNewswire-FirstCall/ -- ATS Medical, Inc. (Nasdaq: ), manufacturer and marketer of state-of-the-art cardiac surgery products and services, today reported that it has received ISO certification for its Quality System to manufacture and CE Mark approval to distribute ATS CryoMaze(TM) cardiac ablation products in the European Union, indicating it is in compliance with...

St. Jude Medical Receives U.S. and European Approvals of EonC, the First Extended-Life Primary Cell Neurostimulator for the Treatment of Chronic Pain

Business Wire (Free subscription) | 08/13/2008

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals of EonC

St. Jude Medical Receives U.S. And European Approvals of EonC, the First Extended-Life Primary Cell Neurostimulator for the Treatment of Chronic Pain

Red Orbit (Free subscription) | 08/13/2008

St. Jude Medical, Inc. (NYSE:STJ) today announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals of EonC(TM), the first extended-life primary cell (non-rechargeable) neurostimulator for the treatment of chronic pain.

• St. Jude Medical Receives U.S. and European Approvals of EonC, the First Extended-Life Primary Cell Neurostimulator for the Treatment of Chronic Pain - Business Wire

St. Jude Medical Announces CE Mark Approval and FDA Clearance for New Family of HIFU Surgical Ablation Products

Business Wire (Free subscription) | 08/18/2008

ST. PAUL, Minn.--(BUSINESS WIRE)--St. Jude Medical, Inc. (NYSE:STJ) has received European CE Mark approval and U.S. Food and Drug Administration (FDA) clearance for the Epicor

St. Jude Medical Announces CE Mark Approval and FDA Clearance for New Family of HIFU Surgical Ablation Products

Red Orbit (Free subscription) | 08/18/2008

St. Jude Medical, Inc. (NYSE:STJ) has received European CE Mark approval and U.S.

EonC, The First Extended-Life Primary Cell Neurostimulator For The Treatment Of Chronic Pain Approved In USA And Europe

Medical News Today (Free subscription) | 08/18/2008

St. Jude Medical, Inc. (NYSE:STJ) announced U.S. Food and Drug Administration (FDA) and European CE Mark approvals of EonC™, the first extended-life primary cell (non-rechargeable) neurostimulator for the treatment of chronic pain. The EonC neurostimulator provides a convenient option for chronic pain patients who prefer or require the simplicity of a non-rechargeable medical device.